DEP irinotecan outperforms irinotecan in cancer models
Filed with ASX · · 6 pages · English
Starpharma Holdings Limited on 6ix
Earlier from Starpharma
- AstraZeneca DEP candidate advance triggers milestone to SPL
- Ansell launches VivaGel condom in Canada
- VivaGel BV phase 3 trials for prevention of BV completed
- Shareholder Update January 2017
- VivaGel BV granted QIDP and Fast Track designation by US FDA
Later from Starpharma
- Starpharma sells Agrochemicals business to Agrium for $35M
- VivaGel BV phase 3 results timing and commercialisation
- Successful VivaGel Phase 3 results and NDA planned for rBV
- Starpharma and Monash awarded STEM Business Fellowships
- DEP docetaxel positive phase 1 results, phase 2 commences
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma